Radice Law Firm is one of class counsel for direct purchaser plaintiffs in an antitrust action alleging an unlawful scheme by Shire and Actavis to monopolize the market for the ADHD medication Intuniv (guanfacine hydrochloride). The case is pending trial in the U.S. District Court for the District of Massachusetts following the court’s denial of Shire’s motions for summary judgment in October 2020.